From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Data retrieval, scrubbing, validation and reconciliation, at scale, is a daunting challenge for most companies, and becomes even more critical for high priced products.
Effective Chargeback Data Management can uncover up to 10-15% gross margin erosion based on the trade partner mix, commercial contract volume, discount levels, and DSA terms
With IntegriChain’s Chargeback Management BPaaS (Business Process as a Service), we offer a full suite of pharmaceutical chargeback data reconciliation and analytics services across Commercial and Government contracts such as GPO/IDN providers, 340B and FSS. Our services marry expert contract management along with unparalleled chargeback verification, uniquely applying the most comprehensive set of validity checks and delivering operational reporting and wholesaler scorecards for more accurate chargeback data management.
For a number of reasons, pharmaceutical manufacturers regularly are forced to spend system and human resources on identifying and resolving chargeback errors. Clearly, wholesaler distribution faces severe margin pressure. Further, widening gaps between 340B contract price and WAC incentivize arbitrage behavior, and trade partners don’t report chargeback reversals on salable returns to inventory up to 90 days after the original sale. In all cases, chargeback errors are difficult to prove without sophisticated analytics, experienced staff, and a robust application for identification of errors.
ICyte Chargeback Application provides:
Streamline your chargeback data.
Commercialization is a critical process for any pharmaceutical manufacturer, with alignment of multiple work streams that span across market access and brand teams as well as finance and the c-suite. We asked three market access leaders with significant launch experience across varying therapeutic categories about their launch journey–from pre-launch strategy and planning to post-launch optimization.
Read the Blog
Updates on US Territory Enrollment Updates, Puerto Rico Medicaid Drug Rebate Program Claims Administrator, TAA Compliance and its Relevance to FSS Agreements, and State Price Transparency Reporting Updates.
